Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several key dosing and indication details for plaque psoriasis are consistent with the label excerpts provided. However, at least one claim is unsupported/incorrectly framed (symptoms and mechanism explanation are not substantiated as stated), and other safety/administration/other factual claims are only partially supported by the provided label excerpts.
Category Scores
Accurate Statements
Stelara (ustekinumab) is administered through injections or infusions to treat moderate to severe plaque psoriasis.
Supported generally by: Indication for moderate to severe plaque psoriasis (1.1) and STELARA route described as subcutaneous for plaque psoriasis in dosing (2.1). Infusion is not shown for plaque psoriasis in provided excerpts.
For plaque psoriasis, Stelara dosing involves an initial subcutaneous injection of 45 mg.
2.1 Recommended Dosage in Plaque Psoriasis: 'For patients weighing 100 kg or less, the recommended dosage is 45 mg initially and 4 weeks later... Administer STELARA subcutaneously at Weeks 0 and 4, then every 12 weeks thereafter.'
For plaque psoriasis, the second dose of Stelara is administered 4 weeks after the initial 45 mg injection.
2.1: '...45 mg initially and 4 weeks later... Administer STELARA subcutaneously at Weeks 0 and 4...'
For patients who respond well to the initial dose of Stelara, maintenance therapy involves injections every 12 weeks.
2.1: '...followed by 45 mg every 12 weeks' and 'Administer... then every 12 weeks thereafter.' (Label provided does not tie maintenance to 'respond well'; it is the recommended regimen.)
Unsupported Statements
Stelara reduces psoriasis symptoms including scaling, redness, and pain by targeting proteins involved in inflammation and immune system activation.
Mechanism in the provided label excerpt (12.1) states ustekinumab binds the p40 subunit used by IL-12/IL-23, but the label excerpts do not specifically support the stated clinical symptom list (scaling, redness, pain) or the exact phrasing 'proteins involved in inflammation and immune system activation' as a direct causal explanation.
Some patients experience side effects of redness, itching, and swelling at the injection site with Stelara.
The provided label excerpts include infections, malignancies, hypersensitivity, PRES, and noninfectious pneumonia, but do not provide support for injection-site specific reactions with the listed symptom terms (redness, itching, swelling).
Rarely, Stelara can cause more severe reactions such as infection or allergic reactions.
The excerpts support infections and serious hypersensitivity reactions (5.1 and 5.5; also 6 discussion), but do not support the qualifier 'rarely' as stated, nor the combined 'infection or allergic reactions' phrasing with a rarity framing.
Currently, there are no biosimilar versions of Stelara available on the market.
The provided FDA label excerpts do not address availability of biosimilars.
Stelara is manufactured by Janssen Biotech, a subsidiary of Johnson & Johnson.
The provided FDA label excerpts do not include manufacturer/sponsor information.
Contradictions
Low
AI Statement
Stelara (ustekinumab) is administered through injections or infusions to treat moderate to severe plaque psoriasis.
Label Reference
2.1 indicates plaque psoriasis dosing is administered subcutaneously (Weeks 0 and 4, then every 12 weeks). The provided excerpts do not state infusions for plaque psoriasis.
Important Omissions
Weight-based plaque psoriasis dosing: label specifies 45 mg for patients weighing 100 kg or less and 90 mg initially and every 12 weeks for patients weighing more than 100 kg.
Importance:
Moderate
Indication population detail: label specifies adults and pediatric patients 6 years of age and older who are candidates for phototherapy or systemic therapy (claim did not mention age range or candidacy criteria).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Dosing appears partially aligned for 45 mg regimen but omits weight-based 90 mg dosing and does not include key safety precautions from the label excerpts (e.g., TB evaluation, immunization guidance, malignancy risk). Some side-effect statements are not supported by the provided label excerpts, which could mislead safety expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Missing material label details (weight-based 45 mg vs 90 mg; age/candidacy criteria) and several claims are unsupported by provided label excerpts (mechanism-to-symptoms explanation, specific injection-site adverse reaction wording, rarity framing, biosimilar/manufacturer statements).
Suggested Improvement
Restrict plaque psoriasis dosing and administration statements strictly to the label excerpt (subcutaneous; include weight-based 45 mg vs 90 mg). Replace symptom/mechanism and adverse reaction descriptions with claims supported in the label excerpts (e.g., IL-12/IL-23 p40 binding; infections and serious hypersensitivity as discussed). Remove or qualify any statements about biosimilar availability and manufacturer unless supported by the provided label sections.